Daratumumab in Primary Antiphospholipid Syndrome

Autoimmune Disorders Clinical Trial

— DARE-APS  

Official title:

Targeting CD38 With Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial (ITN093AI)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05671757
• Other study ID #: DAIT ITN093AI
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: May 26, 2023
• Est. completion date: April 29, 2024

Study information

• Verified date: March 2024
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS). Three daratumumab dosing cohorts are planned with up to six participants in each dosing cohort with the potential to enroll an additional 4 subjects in the highest safe dose (HSD) cohort, for a total of up to 22 participants. The dosing cohorts are: 4 mg/kg, 8 mg/kg, and 16 mg/kg. Each cohort will receive intravenous (IV) administration of daratumumab according to the following schedule, for a total of 8 doses. The primary objective is to determine the safety of daratumumab in APS defined as Dose Limiting Toxicities (DLTs) occurring during the dose escalation phase.

Description:

The trial is a phase 1b open-label study of daratumumab in participants with APS. The study design is a modification of the 3 + 3 dose escalation scheme. Three daratumumab dose cohorts are planned: 4 mg/kg, 8 mg/kg, and 16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48. Dose Escalation Phase Dose escalation will proceed according to safety criteria (Dose Limiting Toxicity, DLT) and efficacy criteria (antiphospholipid antibody negativity). An independent safety committee will review the data and approve escalation to the next dose. The Highest Safe Dose (HSD) is the highest administered dose at which ≤ 1/6 participants experiences a DLT at or prior to week 9. Expansion Phase Four additional participants will be enrolled and treated at the HSD weekly for 8 doses.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 22
• Est. completion date: April 29, 2024
• Est. primary completion date: April 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Adults 18 to 70 years of age, inclusive.

2. The completion of the following vaccinations at least 14 days prior to Visit 0:

1. COVID-19 vaccination series according to the current Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations, and

2. At least one dose of the herpes zoster vaccination series, and

3. Current seasonal influenza vaccine, if available.

3. History of APS according to the updated 2006 Sapporo classification criteria, including at least one of the following: a. Arterial thrombosis, except transient ischemic attack, confirmed by objective validated criteria such as imaging, or b. Venous thrombosis, except superficial thrombophlebitis, confirmed by objective validated criteria such as imaging, or c. Pregnancy morbidity, based on the updated 2006 Sapporo APS classification criteria, or d. Microvascular APS, with at least one of the following: i. Renal biopsy documentation of aPL-associated nephropathy, or ii. Lung biopsy or bronchoalveolar lavage documentation of diffuse alveolar hemorrhage (DAH), or iii. Skin biopsy documentation of livedoid vasculopathy.

4. History of triple positive aPL within the prior 5 years and at least 12 weeks prior to

enrollment, including all of the following:

1. aCL IgG level > Upper Limit of Normal (ULN), and

2. aß2GPI IgG level > ULN, and

3. Positive LA test.

5. Confirmation of triple positive aPL at screening, including all of the following:

1. aCL IgG level = 40 GPL, and

2. aß2GPI IgG level = 40 SGU, and

3. Positive LA test.

6. Willing and able to undergo anticoagulation with warfarin or low molecular weight heparin (LMWH), if there is a history of arterial or venous thrombosis.

7. Willing and able to discontinue direct oral anticoagulants, including factor Xa inhibitors and direct thrombin inhibitors, if applicable.

Exclusion Criteria:

1. Inability or unwillingness to give written informed consent.

2. Inability or unwillingness to comply with study protocol.

3. Systemic autoimmune diseases other than APS, including but not limited to:

1. Systemic lupus erythematosus (SLE) meeting the EULAR/ACR classification criteria.

2. Rheumatoid arthritis meeting the ACR/EULAR classification criteria.

3. Small, medium, and large vessel vasculitis meeting ACR classification criteria.

4. Catastrophic APS classification within the prior 90 days.

5. Acute arterial or venous thrombosis within the prior 30 days.

6. Use of the following medications:

1. Any prior treatment with CD38 targeting monoclonal antibodies, including daratumumab or isatuximab-irfc.

2. Administration of the Janssen COVID-19 vaccine within the prior 14 days.

3. The following within the prior 30 days:

i. Corticosteroids > 10 mg/day prednisone or equivalent. ii. Direct oral anticoagulants (DOACs). iii. Live attenuated vaccines. iv. IVIG or other supplemental immunoglobulin. d. Azathioprine, methotrexate, mycophenolate mofetil, mycophenolate sodium, lefluonomide, or calcineurin inhibitors within the prior 90 days. e. Cyclophosphamide within the prior 90 days. f. Immunomodulatory or immunosuppressive biologic agents, including belimumab, within the prior 90 days or 5 half-lives, whichever is greater. g. Investigational agents within the prior 90 days or 5 half-lives, whichever is greater, except for COVID-19 vaccines and medications for prevention or treatment of COVID-19 per FDA Emergency Use Authorization (EUA). h. Biologic B cell depleting agents including rituximab with any of the following: i. Treatment within the prior 180 days, or ii. CD19+ absolute count < 40/ µl, or iii. Serum IgG <500 mg/dL.

7. Plasma exchange within the prior 90 days.

8. Hemodialysis within the prior 90 days.

9. Major surgical procedure within the prior 60 days.

10. Known allergy, hypersensitivity, or intolerance to boron, malitol, sorbitol, corticosteroids, monoclonal antibodies including daratumumab, human proteins, or their excipients.

11. Allergy, intolerance, or contraindication to acyclovir, valacyclovir, and famciclovir.

12. Active or chronic infection, including the following:

1. Active bacterial, viral, fungal, or opportunistic infection.

2. Chronic infection requiring suppressive antibiotic treatment.

3. Intravenous antibiotics or hospitalization for infection within the prior 30 days.

4. Evidence of current or prior Mycobacterium tuberculosis infection.

5. Human immunodeficiency virus (HIV).

6. Current or prior infection with hepatitis B virus (HBV).

7. Current or prior infection with hepatitis C virus (HCV), except adequately treated HCV with sustained virologic response = 12 weeks.

8. Positive SARS-CoV-2 nucleic acid amplification test (NAAT) within the prior 14 days.

9. History of recurrent herpes zoster, or history of herpes zoster ophthalmicus, disseminated herpes zoster, or disseminated herpes simplex.

13. The following laboratory abnormalities:

ITN093AI: DARE-APS Version 3.0 September 12, 2023 Daratumumab in Primary Antiphospholipid Syndrome

1. Absolute neutrophil count < 1500/mm3.

2. Platelets < 100,000/mm3.

3. Hemoglobin (Hgb) < 10 g/dL.

4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2x the Upper Limit of Normal (ULN).

5. Total bilirubin > 2x ULN, except in the case of congenital bilirubinemia then direct bilirubin > 2x ULN.

6. eGFR < 45 ml/min/1.73 m2.

14. History of primary immunodeficiency.

15. History of solid organ or hematopoietic stem cell transplantation.

16. Comorbidities requiring systemic corticosteroid therapy, including those which have required three or more courses of systemic corticosteroids within the 12 months prior to Visit 0.

17. Any of the following conditions with FEV1 < 70% predicted within the prior 90 days:

1. Asthma.

2. Chronic obstructive pulmonary disease (COPD).

3. DAH.

18. Pulmonary hypertension.

19. Adrenal insufficiency.

20. Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) = 8.0%.

21. Concomitant malignancy or history of malignancy, except adequately treated or excised nonmetastatic squamous cell carcinoma, basal cell skin carcinoma, or cervical carcinoma in situ.

22. Clinically significant cardiac disease, including but not limited to:

1. Myocardial infarction within the prior 6 months, or

2. Unstable or uncontrolled disease or condition related to or affecting cardiac function, including but not limited to: i. Unstable angina, or ii. Congestive heart failure, New York Heart Association Class II-IV, or iii. Uncontrolled cardiac arrhythmia.

23. Current diagnosed mental illness or current diagnosed or self-reported drug or alcohol abuse which, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.

24. Severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease.

25. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or may impact the quality or interpretation of the data obtained from the study.

26. Lack of peripheral venous access.

27. Pregnancy, or planning a pregnancy during the 48 week study duration.

28. Breast-feeding.

29. Unwillingness to use medically acceptable non-prothrombotic contraception if of reproductive potential and engaging in sexual activity that could lead to pregnancy.

Related Conditions & MeSH terms

• Antiphospholipid Syndrome
• Autoimmune Diseases
• Autoimmune Disorders

Intervention

Biological:
• Daratumumab
Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
• Daratumumab
Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
• Daratumumab
Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	Johns Hopkins University	Baltimore	Maryland
United States	Duke University	Durham	North Carolina
United States	Northwell Health	Great Neck	New York
United States	Hospital for Special Surgery	New York	New York
United States	NYU Langone	New York	New York
United States	Weill Cornell	New York	New York
United States	Mayo Clinic Rochester	Rochester	Minnesota

Sponsors (4)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN), PPD, Rho Federal Systems Division, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	MECHANISTIC: The frequency specific immune cell populations in viably cryopreserved Peripheral Blood Mononuclear Cell (PBMC)		At weeks 4, 9, 17, 25, 36 and 48
Other	MECHANISTIC:The functional status of specific immune cell populations in viably cryopreserved Peripheral Blood Mononuclear Cell (PBMC)		At weeks 4, 9, 12, 18, 24, 36 and 48
Other	MECHANISTIC: Immunophenotypin		At weeks 4, 9, 12, 18, 24, 36 and 48
Other	MECHANISTIC: Level of circulating cell		At weeks 4, 9, 12, 18, 24, 36 and 48
Other	MECHANISTIC: The effect of treatment dose on specific cell phenotypes		At weeks 4, 9, 12, 18, 24, 36 and 48
Other	MECHANISTIC: The effect of treatment dose on specific cell profiles		At weeks 4, 9, 12, 18, 24, 36 and 48
Other	MECHANISTIC: Levels of soluble immune mediators		At weeks 4, 9, 12, 18, 24, 36 and 48
Other	MECHANISTIC: Levels of soluble immune antibodies		At weeks 4, 9, 12, 18, 24, 36 and 48
Other	MECHANISTIC: Global changes in gene expression of molecules		At weeks 4, 9, 12, 18, 24, 36 and 48
Primary	The proportion of participants in the dose escalation phase with at least one Dose Limiting Toxicity (DLT)	Proportions will be estimated by dose cohort with 95% confidence intervals derived using the Clopper-Pearson exact method	At or before week 9
Secondary	The proportion of participants with the following Grade 3 or higher adverse events (AEs) related to daratumumab	Adverse events including: Infusion reaction; Neutropenia; Thrombocytopenia; Infection	At or before weeks 9, 24, and 48.
Secondary	The proportion of Grade 2 or higher adverse event (AEs) related to daratumumab	The proportion of participants who experience at least one event will be estimated by dosing level with 90% confidence intervals derived using the Clopper-Pearson exact method	At or before weeks 9, 24, and 48
Secondary	The proportion of participants with negative Lupus Anticoagulant (LA) test	For dichotomous endpoints, including the composite of (a) Negative LA test, and (b) fold-reduction in both aCL IgG and aß2GPI IgG, and the individual components, proportions will be reported with 90% confidence intervals derived using the Clopper-Pearson exact method	At week 9
Secondary	The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG)	For dichotomous endpoints, including the composite of (a) Negative LA test, and (b) fold-reduction in both aCL IgG and aß2GPI IgG, and the individual components, proportions will be reported with 90% confidence intervals derived using the Clopper-Pearson exact method	At week 9 compared to week 0
Secondary	The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels		At week 9 compared to week 0
Secondary	The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG) levels	For dichotomous endpoints, including the composite of (a) Negative LA test, and (b) fold-reduction in both aCL IgG and aß2GPI IgG, and the individual components, proportions will be reported with 90% confidence intervals derived using the Clopper-Pearson exact method	At week 24 compared to week 0
Secondary	The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels	For dichotomous endpoints, including the composite of (a) Negative LA test, and (b) fold-reduction in both aCL IgG and aß2GPI IgG, and the individual components, proportions will be reported with 90% confidence intervals derived using the Clopper-Pearson exact method	At week 48 compared to week 0
Secondary	The proportion of participants with a negative Lupus Anticoagulant (LA) test	For dichotomous endpoints, including the composite of (a) Negative LA test, and (b) fold-reduction in both aCL IgG and aß2GPI IgG, and the individual components, proportions will be reported with 90% confidence intervals derived using the Clopper-Pearson exact method	At weeks 4, 9, 12, 18, 24, 36 and 48
Secondary	The proportion of participants with a negative Lupus Anticoagulant (LA) test	For dichotomous endpoints, including the composite of (a) Negative LA test, and (b) fold-reduction in both aCL IgG and aß2GPI IgG, and the individual components, proportions will be reported with 90% confidence intervals derived using the Clopper-Pearson exact method	At week 24
Secondary	Change in Anti-beta2-glycoprotein test Immunoglobulin G (abeta2GPI IgG) levels	Fold-change from week 0 will be summarized within dosing cohort using descriptive statistics. Additional descriptive statistics may include absolute change and ordinal definitions of antibody levels	From weeks 0 to weeks 4, 9, 12, 18, 24, 36 and 48
Secondary	Change in Anticardiolipin antibodies Immunoglobulin M (aCL IgM) levels	Fold-change from week 0 will be summarized within dosing cohort using descriptive statistics. Additional descriptive statistics may include absolute change and ordinal definitions of antibody levels	From week 0 to weeks 4, 9, 12, 18, 24, 36 and 48
Secondary	The proportion of Grade 2 or higher serious adverse event (SAEs) related to daratumumab	The proportion of participants who experience at least one event will be estimated by dosing level with 90% confidence intervals derived using the Clopper-Pearson exact method	At or before weeks 9, 24, and 48
Secondary	The proportion of participants with at least 50% reduction in Anti-beta2-glycoprotein I antibodies (a-beta2GPI IgG) compared to week 0	For dichotomous endpoints, including the composite of (a) Negative LA test, and (b) fold-reduction in both aCL IgG and aß2GPI IgG, and the individual components, proportions will be reported with 90% confidence intervals derived using the Clopper-Pearson exact method	At week 9
Secondary	The proportion of participants with a negative Lupus Anticoagulant (LA) test	For dichotomous endpoints, including the composite of (a) Negative LA test, and (b) fold-reduction in both aCL IgG and aß2GPI IgG, and the individual components, proportions will be reported with 90% confidence intervals derived using the Clopper-Pearson exact method	At week 48
Secondary	The proportion of participants with at least 50% reduction in Anticardiolipin antibodies Immunoglobulin G (aCL IgG) levels	For dichotomous endpoints, including the composite of (a) Negative LA test, and (b) fold-reduction in both aCL IgG and aß2GPI IgG, and the individual components, proportions will be reported with 90% confidence intervals derived using the Clopper-Pearson exact method	At week 48 compared to week 0

External Links

•   Division of Allergy, Immunology, and Transplantation
•   Immune Tolerance Network
•   National Institute of Allergy and Infectious Diseases